Treatment of Sinusoidal Obstruction Syndrome With Defibrotide in Pediatric Cancer Patients Following Nontransplant-associated Chemotherapy: A Case Report and Review of the Literature.
J Pediatr Hematol Oncol
; 44(3): e788-e791, 2022 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-33902061
Sinusoidal obstruction syndrome (SOS), formerly veno-occlusive disease (VOD), in pediatric cancer patients often presents as a complication of hematopoietic stem cell transplantation, and less commonly secondary to nontransplant-associated chemotherapy. Therapy with defibrotide is well-described as standard care for transplant-associated SOS/VOD, but the treatment of nontransplant-associated SOS/VOD is less clear. We report a 3-year-old with relapsed Wilms tumor and recurrent SOS/VOD, with successful use of defibrotide during chemotherapy. A review of pediatric cancer patients with nontransplant-associated SOS/VOD treated with defibrotide revealed 83 patients, and 66 were in remission. This review supports early treatment with defibrotide in patients with nontransplant-associated SOS/VOD.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hepatopatia Veno-Oclusiva
/
Transplante de Células-Tronco Hematopoéticas
/
Neoplasias Renais
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article